Group 1 - The core viewpoint of the article is that Junsei Biotech has submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor, focusing on innovative cell therapies and drug development for solid tumors [1] - Junsei Biotech specializes in developing safer, more effective, accessible, and affordable immune cell therapies that are not limited by fixed molecular targets, addressing both common and difficult-to-treat solid tumors [1] - The company's flagship product, GC101, is the world's first tumor-infiltrating lymphocyte (TIL) therapy that does not require high-intensity lymphodepletion chemotherapy or IL-2 administration, and it is expected to be the first TIL therapy approved for market in China [1]
新股消息 | 君赛生物递表港交所主板
智通财经网·2025-12-10 10:09